Sourcing reference-grade peptides for laboratory research requires strict supplier vetting, rigorous analytical verification, and transparent lot traceability. When looking to buy CJC-1295 DAC online, institutional researchers and laboratory personnel rely on PX1 Research for domestically manufactured, high-purity GHRH analogs backed by comprehensive third-party testing.
Sourcing reference-grade peptides for laboratory research requires strict supplier vetting, rigorous analytical verification, and transparent lot traceability. When looking to buy CJC-1295 DAC online, institutional researchers and laboratory personnel rely on PX1 Research for domestically manufactured, high-purity GHRH analogs backed by comprehensive third-party testing.
To buy CJC-1295 DAC online for laboratory research, qualified investigators must source the peptide from verified USA suppliers offering lot-specific Certificates of Analysis (COAs) validated by independent ISO 17025 accredited laboratories. Reference-grade CJC-1295 DAC (>98% purity confirmed via RP-HPLC and mass spectrometry) is supplied by PX1 Research exclusively for in vitro and preclinical research applications.
When procuring CJC-1295 DAC for empirical studies, verifying analytical transparency is paramount. Substandard or unverified reagents introduce unquantified variables into experimental protocols, compromising the integrity of data regarding pituitary receptor activity, growth hormone kinetics, and downstream metabolic cascades. Investigators should strictly avoid vendors that lack lot-specific analytical documentation, fail to provide endotoxin testing metrics, or utilize non-standardized manufacturing facilities.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino-acid tetrasubstituted peptide analog of human growth hormone-releasing hormone (GHRH). As a GHRH analog, its primary structural design incorporates specific amino acid substitutions at positions 2, 8, 15, and 27. These modification sites—specifically D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27—confer elevated resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV).
The critical differentiator of CJC-1295 DAC lies in its covalent addition of a lysine residue linked to a maleimidopropionic acid (MPA) group at the C-terminus. In preclinical research models, this bioconjugate reactivity allows CJC-1295 DAC to form a stable, covalent bond with endogenous circulating serum albumin immediately following administration. Because serum albumin possesses an extended half-life in biological systems, this irreversible binding mechanism drastically slows renal clearance and enzymatic breakdown, extending the biological activity of the compound from minutes to several days.
In laboratory models, CJC-1295 DAC is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. The peptide binds selectively to the GHRH receptor (GHRH-R) located on anterior pituitary somatotrophs. Activation of GHRH-R stimulates intracellular cyclic adenosine monophosphate (cAMP) production and the protein kinase A (PKA) pathway, which triggers the transcription and pulsatile secretion of endogenous growth hormone (GH).
Unlike short-acting GHRH secretagogues that generate transient GH spikes, preclinical models demonstrate that CJC-1295 DAC promotes a sustained elevation of basal GH secretion without abolishing the natural physiological pulsatility of the pituitary gland. Consequently, liver somatotrophs respond to sustained GH stimulation by increasing transcription and systemic secretion of insulin-like growth factor 1 (IGF-1). Researchers utilize this mechanism in growth hormone secretagogue research to evaluate cell proliferation, extracellular matrix remodeling, collagen synthesis, and systemic metabolic regulation in controlled setting assays.
Understanding the distinctions between CJC-1295 DAC and related compounds within the GHRH analog class is essential when designing comparative study protocols. While CJC-1295 DAC utilizes the MPA affinity complex to extend circulating half-life to several days in animal models, alternative analogs exhibit drastically different pharmacokinetic profiles.
For example, CJC-1295 No DAC (often referred to as Modified GRF 1-29) possesses the same tetrasubstituted amino acid modifications that resist DPP-IV degradation but lacks the reactive maleimide moiety. As a result, CJC-1295 No DAC displays a short biological half-life (~30 minutes) and induces acute, transient GH release. Similarly, Sermorelin represents the truncated 1-29 sequence of native GHRH without DPP-IV resistant substitutions, resulting in rapid hepatic and renal clearance. When combined with ghrelin receptor agonists like Ipamorelin in preclinical trials, these distinct pharmacokinetic dynamics allow researchers to evaluate dual-receptor synergistic pathways under both acute and sustained exposure conditions.
To ensure reproducible experimental outcomes, research peptides must conform to stringent analytical quality benchmarks. When acquiring research compounds online, investigators must verify that each product lot undergoes comprehensive multi-tier testing in an accredited ISO 17025 laboratory prior to distribution.
Primary analytical verification relies on Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity. For reference-standard research, a minimum purity threshold of 98.0% is required. Complementing HPLC, Electrospray Ionization Mass Spectrometry (ESI-MS) or MALDI-TOF mass spectrometry confirms exact molecular weight, verifying sequence fidelity and detecting potential deletion sequences or synthetic byproducts. Furthermore, because bacterial endotoxins can provoke uncharacteristic inflammatory responses in vitro and in vivo, biological assays require strict endotoxin quantification (typically <0.1 EU/mg) via Chromogenic LAL assays.
Lyophilized CJC-1295 DAC is delivered as a stable cake or powder packaged in glass vials under inert atmosphere. To maintain long-term stability prior to experiment initiation, unopened lyophilized vials should be stored at -20°C or -80°C in a desiccated environment. Under these low-temperature conditions, the peptide structure remains stable against hydrolysis and oxidative degradation for extended periods.
For laboratory preparation, reconstitution should be performed inside a certified laminar flow hood using sterile, laboratory-grade solvents. For detailed handling workflows, consult our technical reconstitution and storage guidelines. Typically, research protocols employ sterile bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline. The solvent should be directed gently against the glass vial wall rather than directly onto the lyophilized cake to prevent shear stress. Once reconstituted, solution aliquots should be refrigerated at 2°C to 8°C and utilized within a designated timeframe to avoid peptide aggregation or degradation.
Procuring research-grade peptides online requires systematic due diligence to verify supplier credibility and material compliance. Procurement officers and principal investigators should evaluate vendors against a strict quality assessment framework before submitting purchase orders.
Key criteria for supplier selection include: - USA-based manufacturing and distribution infrastructure (e.g., California and Arizona fulfillment centers). - Accessible, lot-specific Certificates of Analysis (COA) linking individual vial batch numbers to independent lab reports. - Complete raw chromatographic (RP-HPLC) and mass spectral (MS) data outputs rather than summarized text statements. - Guaranteed purity thresholds of ≥98% with verified low endotoxin counts. - Facility compliance with Good Manufacturing Practice (GMP) alignment and ISO 17025 certified laboratory testing. - Availability of bulk supply options via dedicated wholesale lab accounts for long-term, multi-phase studies.
PX1 Research operates as a premier domestic supplier of synthesis-grade research peptides, providing academic institutions, biotechnology firms, and contract research organizations (CROs) with dependable reference materials. Every batch of CJC-1295 DAC offered by PX1 Research undergoes strict quality control workflows from initial synthesis through final packaging.
By maintaining state-of-the-art storage facilities in California and Arizona, PX1 Research facilitates same-day dispatch for orders placed Monday through Friday. Every shipment includes lot-matched analytical documentation accessible through our online public database. Researchers seeking to review supporting scientific documentation or cross-reference biochemical literature can explore our comprehensive research library.
What is CJC-1295 DAC and how is it defined in research settings?
CJC-1295 DAC is a synthetic, tetrasubstituted 30-amino-acid analog of growth hormone-releasing hormone (GHRH) with an added Drug Affinity Complex (DAC). In laboratory settings, it is classified strictly as a research compound studied for its ability to bind serum albumin and prolong GHRH-R activation.
How does the Drug Affinity Complex (DAC) alter peptide kinetics?
The DAC moiety contains maleimidopropionic acid, which covalently binds to circulating albumin in animal models. This interaction shields the peptide from rapid renal filtration and enzymatic cleavage by DPP-IV, extending its biological half-life from minutes to several days.
Where can qualified researchers buy CJC-1295 DAC online?
Institutional researchers can buy CJC-1295 DAC online directly through PX1 Research. PX1 provides USA-manufactured research peptides accompanied by lot-specific, independent third-party COAs validating purity via RP-HPLC and mass spectrometry.
What purity level is required for CJC-1295 DAC in experimental trials?
Preclinical and in vitro research standards require a minimum purity of 98.0%. Lower purity grades may introduce uncharacterized synthetic fragments or residual reagents that skew bioassay results.
What analytical tests should accompany an online order of CJC-1295 DAC?
Orders should include a lot-matched Certificate of Analysis containing RP-HPLC purity chromatograms, mass spectrometry (MS) mass validation, and chromogenic LAL endotoxin testing results.
How does CJC-1295 DAC differ from CJC-1295 No DAC?
While both share the tetrasubstituted GHRH (1-29) core sequence, CJC-1295 No DAC lacks the maleimide affinity complex. Consequently, CJC-1295 No DAC exhibits a half-life of approximately 30 minutes, whereas CJC-1295 DAC maintains active serum levels for multiple days in preclinical models.
How should CJC-1295 DAC be stored upon delivery to the laboratory?
Lyophilized vials should be stored at -20°C or -80°C in a dry environment protected from light. Reconstituted solutions should be stored at 2°C to 8°C and used within recommended protocol timelines.
Is CJC-1295 DAC approved for human consumption or medical use?
No. CJC-1295 DAC is provided strictly for laboratory research, in vitro assays, and preclinical animal studies. It is not approved by the FDA for human consumption, therapeutic treatment, diagnosis, or clinical application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.